AtheroGenics, Inc.’s AGI-1067, which is being developed in partnership with AstraZeneca, did not meet its primary endpoint in a Phase III trial. AGI-1067 is aimed at reducing the buildup of plaque inside arteries by addressing the inflammation behind heart disease. The study compared the effect of AGI-1067 to placebo in more than 6,000 patients with heart disease on the time to first incidence of a composite of major adverse cardiovascular events such as resuscitated cardiac arrest, h...